GlassScriptPhysician profile
Kyle Kragenbrink
NPI 1437598992
$4,048.96
in general payments reported to CMS, 2019-2025
15 companies · $918 in 2025
The $918 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $923 · 2020: $486 · 2021: $538 · 2022: $380 · 2023: $291 · 2024: $513 · 2025: $918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,721.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $739.13 | 2024-2025 | Vevye |
| Alcon Vision LLC | $578.69 | 2021-2025 | Precision7, Total30 |
| Novartis Pharmaceuticals Corporation | $545.71 | 2019-2022 | |
| Allergan, INC. | $438.88 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $410.87 | 2020-2021 | |
| Coopervision INC. | $312.27 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $265.31 | 2022-2025 | Miebo, Xiidra |
| Carl Zeiss Meditec, INC. | $196.26 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $165.00 | 2023-2024 | Acuvue |
| Dompe US, INC. | $123.26 | 2024 | Oxervate |
| Oyster Point Pharma, INC. | $85.33 | 2022-2024 | Tyrvaya |
| Aerie Pharmaceuticals, INC. | $79.33 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $54.01 | 2024-2025 | Xdemvy |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Eyevance Pharmaceuticals LLC | $16.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Kragenbrink listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.